ArticleIndian journal of endocrinology and metabolism2013
Atherogenic dyslipidemia.
Article in Indian journal of endocrinology and metabolism, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 106 citations in OpenAlex.
- Consumption of Eggs Alone or Enriched with Annatto (Nutrients · 2023Trial
- Apolipoprotein B and angiotensin-converting enzyme polymorphisms and aerobic interval training: randomized controlled trial in coronary artery disease patients.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2018Trial
- Article
- Management of late toxicities and specific follow-up needs of adolescent and young adult cancer survivors: recommendations from scientific societies in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Article
- The modified cardiometabolic index as a simple screening tool for cardiovascular disease risk: a cohort study.Scientific reports · 2025Article
- Article
- Review
- Maternal lipids in overweight and obesity: implications for pregnancy outcomes and offspring's body composition.Seminars in immunopathology · 2025Review
- The combined effects of cardiometabolic index and high-sensitivity C-reactive protein on the risk of new onset stroke in a Chinese national prospective longitudinal cohort study.Lipids in health and disease · 2025Article
- Association between Atherogenic Dyslipidemia and Subclinical Myocardial Injury in the General Population.Journal of clinical medicine · 2024Article
- TheInnate immunity · 2024Article
- Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024.Obesity pillars · 2024Article
- Management of triglycerides, non-high density lipoprotein cholesterol and high density lipoprotein cholesterol.Indian heart journal · 2024Review
- Selenium Biomarkers and Their Relationship to Cardiovascular Risk Parameters in Obese Women.Biological trace element research · 2024Article
- Lipid Disorders Management Strategies (2024) in Prediabetic and Diabetic Patients.Pharmaceuticals (Basel, Switzerland) · 2024Review
- The value of Lp(a) and TG/HDLC in peripheral blood to assess the stability of carotid plaque in patients with ischemic stroke.Brain and behavior · 2024Article
- Dietary Effects of Fasting on the Lipid Panel.Current cardiology reviews · 2024Review
- Role of FGF21 and Leptin for the Diagnosis of Metabolic Health in Children with and without Obesity.Journal of personalized medicine · 2023Article
- Deteriorative Effect of a Combination of Hypertriglyceridemia and Low High-Density Lipoprotein Cholesterolemia on Target Lesion Revascularization after Everolimus-Eluting Stent Implantation.Journal of atherosclerosis and thrombosis · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherogenic dyslipidemia (AD) refers to elevated levels of triglycerides (TG) and small-dense low-density lipoprotein and low levels of high-density lipoprotein cholesterol (HDL-C). In addition, elevated levels of large TG rich very low-density lipoproteins, apolipoprotein B and oxidised low-density lipoprotein (LDL), and reduced levels of small high-density lipoproteins plays a critical role in AD. All three elements of AD per se have been recognised as independent risk factor for cardiovascular disease. LDL-C/HDL-C ratio has shown excellent risk prediction of coronary heart disease than either of the two risk markers. Asian Indians have a higher prevalence of AD than western population due to higher physical inactivity, low exercise and diet deficient in polyunsaturated fatty acids (PUFA). The AD can be well managed by therapeutic lifestyle changes with increased physical activities, regular exercise, and diets low in carbohydrates and high in PUFA such as omega-3-fatty acids, as the primary intervention. This can be supplemented drug therapies such as statin monotherapy or combination therapy with niacin/fibrates. Rosuvastatin is the only statin, presently available, to effectively treat AD in diabetes and MS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.